MR 4log and low levels of NK cells are associated with higher molecular relapse after imatinib discontinuation: Results of a prospective trial

Seguro, Fernanda Salles; Maciel, Felipe Vr; Santos, Fernanda Maria; Abdo, André; Pereira, Thales; Nardinelli, Luciana; Rocha, Vanderson; Bendit, Israel

doi:10.1016/j.leukres.2021.106516

Cited by 6 publications

(13 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 A single-center, prospective, pilot cohort clinical trial conducted by Seguro et al enrolled 31 patients with CML-CP. 20 All participants were monitored in the same laboratory since diagnosis using qRT-PCR, with a sensitivity of at least MR5. The results showed that a more profound molecular response (MR4.5) was associated with a lower risk of molecular relapse.…”

Section: Current Guidelines For Tfrmentioning

confidence: 99%

“…A single‐center, prospective, pilot cohort clinical trial conducted by Seguro et al. enrolled 31 patients with CML‐CP 20 . All participants were monitored in the same laboratory since diagnosis using qRT‐PCR, with a sensitivity of at least MR5.…”

Section: Monitoring Before Tki Discontinuationmentioning

confidence: 99%

“…All participants were monitored in the same laboratory since diagnosis using qRT‐PCR, with a sensitivity of at least MR5. The results showed that a more profound molecular response (MR4.5) was associated with a lower risk of molecular relapse 20 . In the TKI discontinuation trial, qRT‐PCR with a sensitivity of at least 0.01% (4 log reduction or MR4) on the International Scale (IS) was the standard definition of DMR 21 .…”

Section: Monitoring Before Tki Discontinuationmentioning

confidence: 99%

“…31,32 A similar situation was observed with respect to whether the transcription type affected TFR; some studies found the expression of e14a2 to be associated with a higher rate of TFR, 33,34 although the results of other studies showed no significant relationship between transcription type and TFR. 20,35 Recent studies have suggested that at least some of these differences between patients with e13a2 and e14a2 transcript types can be explained by technical factors, in addition to the different potential biological roles of the oncoproteins that each translates. [36][37][38] Since the e13a2 transcript is reduced by 75 bp compared to the e14a2 transcript, qRT-PCR had a higher amplification efficiency for e13a2 than e14a2.…”

Section: Type Of Bcr::abl1 Transcriptsmentioning

confidence: 99%

See 3 more Smart Citations

Exploration of treatment‐free remission in CML, based on molecular monitoring

Zhang,

Zhou,

Zhou

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

BackgroundTypical chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm caused by t(9; 22)(q34; q11) translocation. This chromosomal translocation forms the BCR::ABL1 fusion gene. The tyrosine kinase encoded by the BCR::ABL1 is considered to be the main pathogenic diver. BCR::ABL1 is not only a therapeutic target, but also a monitoring target. Monitoring of BCR::ABL1 reveals the progression of the disease and guides the next treatment. Now for CML, the target of treatment has been focused on treatment‐free remission (TFR).MethodsWe conducted a literature review of current developments of treatment‐free remission and molecular monitoring methods.ResultsMore effective and sensitive CML monitoring methods such as digital droplet PCR (ddPCR) and next generation sequencing (NGS) have further studied the measurable residual disease (MRD) and clonal heterogeneity, which provides strong support for the exploration of TFR. We discussed some of the factors that may be related to TFR outcomes at the molecular level, along with some monitoring strategies.ConclusionCurrently, predictive indicators for treatment‐free remission outcomes and recurrence are lacking in clinical practice. In future, treatment‐free remission research should focus on combining the clinical indicators with molecular monitoring and biological markers to personalize patient conditions and guide clinicians to develop individualized treatment plans, so that more patients with CML can achieve safer and stabler treatment‐free remission.

show abstract

Section: Current Guidelines For Tfrmentioning

confidence: 99%

Section: Monitoring Before Tki Discontinuationmentioning

confidence: 99%